Results 111 to 120 of about 1,567 (130)
<i>In vitro</i> activity of ceftaroline against clinical isolates of Gram-positive bacteria in paediatric patients: ATLAS programme 2018-2023. [PDF]
JAC Antimicrob ResistKiratisin P +3 more
europepmc +1 more source
Ceftaroline pharmacokinetics/pharmacodynamics in the hollow-fibre model of <i>Mycobacterium abscessus</i> lung disease. [PDF]
IJTLD OpenFerro BE, Srivastava S, Gumbo T.
europepmc +1 more source
Off-label use of ceftaroline fosamil: A systematic review [PDF]
International Journal of Antimicrobial Agents, 2019 Ceftaroline fosamil is a fifth-generation cephalosporin with anti-methicillin-resistant Staphylococcus aureus (MRSA) activity. It has been approved by the EMA and FDA for the treatment of adults and children with community-acquired bacterial pneumonia ...
Daniele Pastori +2 more
exaly +4 more sources
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials [PDF]
International Journal of Antimicrobial Agents, 2019 This post-hoc analysis compared the pharmacokinetics and clinical outcomes of ceftaroline fosamil 600 mg every 12 (q12h)versus every 8 hours (q8h)in patients with acute bacterial skin and skin-structure infection (ABSSSI)and signs of sepsis.
Shampa Das +2 more
exaly +2 more sources
Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil [PDF]
Clinical Pharmacology in Drug Development, 2019 Efficacy of ceftaroline fosamil, the prodrug of the active metabolite ceftaroline, was demonstrated in a phase 3 study of hospitalized Asian patients with Pneumonia Outcomes Research Team (PORT) risk class III–IV community-acquired pneumonia (NCT01371838)
Nidal Al-Huniti +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches: